公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2009 | Bibw 2992, a Novel Irreversible Egfr/Her2 Tyrosine Kinase Inhibitor, in Chemonaive Patients with Adenocarcinoma of the Lung and Activating Egfr Mutations | YANG, CHIH-HSIN; SHIH, JIN-YUAN | JOURNAL OF THORACIC ONCOLOGY | | | |
2009 | Biomarker Analyses from a Phase Iii, Randomized, Open-Label, First-Line Study of Gefitinib (G) Versus Carboplatin/Paclitaxel (C/P) in Clinically Selected Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) in Asia (Ipass) | YANG, CHIH-HSIN | JOURNAL OF CLINICAL ONCOLOGY | | | |
2009 | Clinical Outcomes of Patients with Epidermal Growth Factor Receptor (Egfr ) Mutations (Mut) in Ipass (Iressatm Pan Asia Study) | CHAO, TSU-YI; YANG, CHIH-HSIN | JOURNAL OF THORACIC ONCOLOGY | | | |
2008 | Effects of activating epidermal growth factor receptor mutations on clinical response | Gow, Chien-Hung; Chien, Chun-Ru; Chang, Yih-Leong; Chiu, Yueh-Hsai; Kuo, Sung-Hsin; Shih, Jin-Yuan; Chang, Yeun-Chung; Yu, Chong-Jen; Yang, Chih-Hsin; Yang, Pan-Chyr | Clin Cancer Res | | | |
2009 | Efficacy of Pemetrexed-Cisplatin (Pc) in East Asian Patients (Pts): Subgroup Analysis of a Phase Iii Study Comparing Pc Versus Gemcitabine- Cisplatin (Gc) in First-Line Treatment of Advanced Non-Small Cell Lung Cancer (Nsclc) | YANG, CHIH-HSIN | JOURNAL OF CLINICAL ONCOLOGY | | | |
2009 | Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma | YANG, CHIH-HSIN | NEW ENGLAND JOURNAL OF MEDICINE | | | |
2009 | An Open-Label Single-Arm Phase Iv Study of Pemetrexed in Taiwanese Patients with Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy | CHANG, GEE-CHEN; TSAI, CHUN-MING; HSIA, TE-CHUN; YANG, CHIH-HSIN | JOURNAL OF THORACIC ONCOLOGY | | | |
2005 | A Phase Ii Study in Taiwan with Navelbine(Nvb) Oral in Combinatino with Cisplatin (C) in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients | YU, CHONG-JEN; YANG, CHIH-HSIN; CHENG, ANN-LII; YANG, PAN-CHYR; 鄭安理; 楊泮池 | LUNG CANCER | | | |
2009 | A Phase Ii Study of Bibw 2992, a Novel Irreversible Dual Egfr and Her2 Tyrosine Kinase Inhibitor (Tki), in Patients with Adenocarcinoma of the Lung and Activating Egfr Mutations after Failure of One Line of Chemotherapy (Lux-Lung 2) | YANG, CHIH-HSIN | JOURNAL OF CLINICAL ONCOLOGY | | | |
2009 | Phase Iib/Iii Double-Blind Randomized Trial of Bibw 2992, an Irreversible, Dual Inhibitor of Egfr and Her2 Plus Best Supportive Care (Bsc) Versus Placebo Plus Bsc in Patients with Nsclc Failing 1-2 Lines of Chemotherapy (Ct) and Erlotinib or Gefitinib (Lu | YANG, CHIH-HSIN | JOURNAL OF CLINICAL ONCOLOGY | | | |
2010 | Quality of Life (Qol) in a Randomized Phase Iii First-Line Study of Gefitinib (G) Vs Carboplatin/Paclitaxel (Cp) in Clinically Selected Asian Patients (Pts) with Advanced Nsclc (Ipass) | YANG, CHIH-HSIN | JOURNAL OF THORACIC ONCOLOGY | | | |
2008 | Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemonaive NSCLC patients receiving first-line gefitinib monotherapy | Yang, Chih-Hsin; Yu, Chong-Jen; Shih, Jin-Yuan; Chang, Yeun-Chung; Hu, Fu-Chang; Tsai, Meng-Chin; Chen, Kuan-Yu; Lin, Zhong-Zhe; Huang, Ching-Ju; Shun, Chia-Tung; Huang, Chin-Lun; Bean, James; Cheng, Ann-Lii; Pao, William; Yang, Pan-Chyr | J Clin Oncol | | | |
2009 | Vandetanib Plus Pemetrexed Versus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc): A Randomized, Double-Blind Phase Iii Trial (Zeal) | YANG, CHIH-HSIN | JOURNAL OF CLINICAL ONCOLOGY | | | |
2009 | Vandetanib Plus Pemetrexed Vs Pemetrexed as 2nd-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (Nsclc); a Randomized, Double- Blind Phase Iii Trial | YANG, CHIH-HSIN | EJC SUPPLEMENTS | | | |
2009 | Vandetanib Plus Pernetrexed Versus Pemetrexed as 2nd-Line Therapy in Patients with Advanced Nsclc: A Randomized, Double-Blind Phase Iii Trial ( Zeal) | YANG, CHIH-HSIN | JOURNAL OF THORACIC ONCOLOGY | | | |